Attention-Deficit/Hyperactivity Disorder clinical trials at UCLA
4 research studies open to eligible people
Assessing Mobile Apps for Adult ADHD
open to eligible people ages 18-50
The purpose of this clinical trial is to evaluate the effects of mobile app digital therapies on cognitive function and symptoms in adults diagnosed with ADHD.
Los Angeles, California and other locations
Trigeminal Nerve Stimulation for ADHD
open to eligible people ages 7-12
This study is a large multisite randomized clinical trial to asses the efficacy of external trigeminal nerve stimulation (TNS), a novel, minimal risk, non-invasive neuromodulation treatment, for ADHD in children ages 7-12 years old (N=180). Study hypotheses address potential differences in ADHD symptoms over 4 weeks treatment with active vs. sham TNS in an expanded multi-site investigation; whether resting state fronto-parietal connectivity mediates TNS impact on ADHD symptoms; if changes in fronto-parietal activation, as measured by electroencephalography (EEG), predict TNS-related treatment outcomes; and whether a baseline cognitive profile similarly predicts response to TNS therapy.
Los Angeles, California and other locations
Flashed Light Therapy for Adolescents With ADHD and Delayed Sleep Timing
open to eligible people ages 14-17
The primary aim of the present research project is to examine the feasibility, as measured by treatment perceptions, and tolerability, as measured by adherence and attrition, of two weeks of flashed light therapy alone followed by four weeks of daily flashed light therapy combined with four weekly videoconference-delivered cognitive behavioral therapy sessions targeting circadian rhythms and sleep in four adolescents aged 14 to 17 years with attention-deficit/hyperactivity disorder and delayed sleep-wake schedules.
Los Angeles, California
Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
open to eligible people ages 0-20
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Los Angeles, California and other locations
Our lead scientists for Attention-Deficit/Hyperactivity Disorder research studies include Jaime Deville Sandra K. Loo, Ph.D. Emily J Ricketts, Ph.D..
Last updated: